Loading
Alercell
Alercell Inc. is a precision oncology company developing AI-powered epigenetic diagnostic platforms for the early detection of hematologic malignancies. The company's proprietary LENA Platform™ analyzes DNA methylation patterns to detect pre-leukemic signatures up to 41 months before clinical symptom onset, validated across more than 199,000 electronic medical records. Core technologies include the LENA Code™, LENA Score™, Deep Leukemic Cloud Platform™, and Alercell Epigenetic Clock™. Alercell is headquartered in Bozeman, Montana and is currently raising a Series A financing round to advance clinical validation and regulatory strategy.
Funding
Every round, secondary, debt facility or acquisition involving Alercell that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—